Journal Article Summary
The article investigates the transition from methylphenidate (MPH) to lisdexamfetamine (LDX) in treating attention-deficit/hyperactivity disorder (ADHD) among school-aged children. This topic is significant because ADHD is a prevalent neurodevelopmental disorder that can severely impact a child's academic and social life. Understanding the reasons for switching medications and the outcomes of such changes can help improve treatment strategies and patient care.
The study analyzed medical records of 394 children aged 7 to 13 who switched from MPH to LDX at a Danish outpatient clinic between 2013 and 2019. The findings revealed that about 20% of the children switched medications, primarily due to adverse effects and lack of effectiveness of MPH or atomoxetine (ATX). The most common side effects reported with LDX included decreased appetite, insomnia, and irritability. Notably, many children continued LDX treatment for over a year, although continuation rates were lower for those who had switched due to adverse effects from MPH.
However, the study has limitations, including its retrospective design, which may affect the reliability of the data collected. Additionally, the analysis did not account for various factors such as the specific formulations of MPH used or the reasons behind the discontinuation of treatment. Patients and caregivers should discuss these findings with healthcare professionals to understand the potential benefits and risks of switching ADHD medications, as well as to explore personalized treatment options based on individual needs and responses to medication.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Søndergaard Nanna Roed, Nørøxe Karen Busk, Carlsen Anders Helles, Randing Stine Helene, Warrer Pernille, Thomsen Per Hove, Clausen Loa. Switch to Lisdexamfetamine in the Treatment of Attention-Deficit Disorder at a Psychiatric Outpatient Clinic for School-Aged Children: A Danish Cohort Study. Journal of Child and Adolescent Psychopharmacology 2024. DOI: 10.1089/cap.2023.0077. PMID: 38608011. PMCID: PMC11040185.
Featured Pill Pals Product
Atomoxetine 60 mg Capsules --- Generic for Strattera --- Glenmark
Atomoxetine 60 mg Capsules — Generic for Strattera — Glenmark is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
